Myovant Sciences

Myovant Sciences company information, Employees & Contact Information

Explore related pages

Related company profiles:

This page is no longer active or monitored. Myovant Sciences Inc. is now Sumitomo Pharma America (SMPA), while Myovant Sciences GmbH is Sumitomo Pharma Switzerland GmbH (SMPS). We are a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need. See pinned post for our new page and follow us! ⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀ ==== We aspire to be the leading healthcare company focused on redefining care for women’s health and prostate cancer. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer. We strive to improve the lives of millions of people, while building an innovative, dynamic, and collaborative company where employees thrive. Read our LinkedIn Community Guidelines at http://myovant.com/community-guidelines

Company Details

Employees
89
Founded
-
Address
2000 Sierra Point Parkway, 9th Floor,switzerland
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Brisbane, CA
Looking for a particular Myovant Sciences employee's phone or email?

Myovant Sciences Questions

News

Sumitovant Biopharma Completes Acquisition of Myovant Sciences - PR Newswire

Sumitovant Biopharma Completes Acquisition of Myovant Sciences PR Newswire

Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022 - Yahoo Finance

Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022 Yahoo Finance

Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022 - GlobeNewswire

Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022 GlobeNewswire

NCCN awards funding to 4 advanced prostate cancer research projects - Urology Times

NCCN awards funding to 4 advanced prostate cancer research projects Urology Times

Myovant agrees to sell after buyer ups price - BioPharma Dive

Myovant agrees to sell after buyer ups price BioPharma Dive

Weeks after Rejecting First Offer, Myovant Agrees to Acquisition by Sumitovant - BioSpace

Weeks after Rejecting First Offer, Myovant Agrees to Acquisition by Sumitovant BioSpace

Relugolix demonstrates positive phase 3 data as combination therapy for endometriosis pain - Contemporary OB/GYN

Relugolix demonstrates positive phase 3 data as combination therapy for endometriosis pain Contemporary OB/GYN

Orgovyx Approved for Advanced Prostate Cancer - Medical Professionals Reference

Orgovyx Approved for Advanced Prostate Cancer Medical Professionals Reference

Myovant endometriosis survey shows women consider quitting work, school due to symptoms - Fierce Pharma

Myovant endometriosis survey shows women consider quitting work, school due to symptoms Fierce Pharma

Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement - PR Newswire

Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement PR Newswire

Myovant Sciences Appoints Industry Veteran David Marek as Chief Executive Officer - Yahoo Finance

Myovant Sciences Appoints Industry Veteran David Marek as Chief Executive Officer Yahoo Finance

Myovant Sciences and Accord Healthcare, Ltd. Enter into - GlobeNewswire

Myovant Sciences and Accord Healthcare, Ltd. Enter into GlobeNewswire

Myovant rejects $2.4B buyout offer from Japanese majority owner - BioPharma Dive

Myovant rejects $2.4B buyout offer from Japanese majority owner BioPharma Dive

FDA accepts Myfembree sNDA for bleeding associated with uterine fibroids - Contemporary OB/GYN

FDA accepts Myfembree sNDA for bleeding associated with uterine fibroids Contemporary OB/GYN

Myovant Sciences and Pfizer Announce Collaboration to - GlobeNewswire

Myovant Sciences and Pfizer Announce Collaboration to GlobeNewswire

Sumitovant Biopharma Has a Strong Fourth Quarter with Significant Clinical Development and Corporate Achievements Across its Portfolio of Companies - PR Newswire

Sumitovant Biopharma Has a Strong Fourth Quarter with Significant Clinical Development and Corporate Achievements Across its Portfolio of Companies PR Newswire

FDA approves Myfembree for endometriosis pain - Contemporary OB/GYN

FDA approves Myfembree for endometriosis pain Contemporary OB/GYN

UPDATE - Sumitovant Biopharma Announces Myovant Sciences - GlobeNewswire

UPDATE - Sumitovant Biopharma Announces Myovant Sciences GlobeNewswire

Myovant Sciences Ltd. Announces Pricing of Initial Public Offering - PR Newswire

Myovant Sciences Ltd. Announces Pricing of Initial Public Offering PR Newswire

Myovant Sciences Announces Appointment of Board of Directors - PR Newswire

Myovant Sciences Announces Appointment of Board of Directors PR Newswire

Myovant Sciences and Flo Health Partner to Develop Digital Tool to Screen Women for Heavy Menstrual Bleeding - PR Newswire

Myovant Sciences and Flo Health Partner to Develop Digital Tool to Screen Women for Heavy Menstrual Bleeding PR Newswire

Myovant scores FDA nod for Orgovyx, a first-in-class pill for advanced prostate cancer - Fierce Pharma

Myovant scores FDA nod for Orgovyx, a first-in-class pill for advanced prostate cancer Fierce Pharma

Sumitomo's improved buyout offer sways Myovant - FirstWord Pharma

Sumitomo's improved buyout offer sways Myovant FirstWord Pharma

Sumitomo nets Myovant in $2.9B buyout, adding IVF asset to pipeline - Fierce Biotech

Sumitomo nets Myovant in $2.9B buyout, adding IVF asset to pipeline Fierce Biotech

After delay, Myovant and Pfizer's Myfembree nabs FDA nod for endometriosis - Fierce Pharma

After delay, Myovant and Pfizer's Myfembree nabs FDA nod for endometriosis Fierce Pharma

Sumitomo Offers to Buy All of Myovant in Deal Worth $2.5 Billion - Bloomberg

Sumitomo Offers to Buy All of Myovant in Deal Worth $2.5 Billion Bloomberg

Myovant and Pfizer's uterine fibroids med scores FDA nod, setting up showdown with AbbVie - Fierce Pharma

Myovant and Pfizer's uterine fibroids med scores FDA nod, setting up showdown with AbbVie Fierce Pharma

Sumitovant Biopharma’s Portfolio of Innovative Companies - GlobeNewswire

Sumitovant Biopharma’s Portfolio of Innovative Companies GlobeNewswire

Myovant, Pfizer's expansion bid for Myfembree hits a snag at the FDA - Fierce Pharma

Myovant, Pfizer's expansion bid for Myfembree hits a snag at the FDA Fierce Pharma

Myovant leans on new partner Pfizer as it dives into first launch for cancer drug Orgovyx - Fierce Pharma

Myovant leans on new partner Pfizer as it dives into first launch for cancer drug Orgovyx Fierce Pharma

Myovant and Pfizer Ink $4.2 Billion Deal for Orgovyx in Oncology and Women’s Health - BioSpace

Myovant and Pfizer Ink $4.2 Billion Deal for Orgovyx in Oncology and Women’s Health BioSpace

Myovant's endometriosis med hits the mark in phase 3, setting up AbbVie face-off - Fierce Biotech

Myovant's endometriosis med hits the mark in phase 3, setting up AbbVie face-off Fierce Biotech

Sumitovant Biopharma Acquires Women’s Health Pharma Company Myovant Sciences for $1.7B - Femtech Insider

Sumitovant Biopharma Acquires Women’s Health Pharma Company Myovant Sciences for $1.7B Femtech Insider

As Pfizer, Myovant's bid to expand Myfembree use draws near, Myovant teases speedy launch plans - Fierce Pharma

As Pfizer, Myovant's bid to expand Myfembree use draws near, Myovant teases speedy launch plans Fierce Pharma

Myovant bumps IPO to $218M with Pfizer, BB Biotech aid - Fierce Biotech

Myovant bumps IPO to $218M with Pfizer, BB Biotech aid Fierce Biotech

Myovant, Gedeon Richter’s uterine fibroids med Ryeqo bags EU approval - PharmaTimes

Myovant, Gedeon Richter’s uterine fibroids med Ryeqo bags EU approval PharmaTimes

Asian trial backs Takeda and Myovant’s relugolix in uterine fibroids - Fierce Biotech

Asian trial backs Takeda and Myovant’s relugolix in uterine fibroids Fierce Biotech

Myovant Sciences Ltd. (MYOV) Q1 2021 Earnings Call Transcript - The Motley Fool

Myovant Sciences Ltd. (MYOV) Q1 2021 Earnings Call Transcript The Motley Fool

Takeda and Roivant launch Myovant Sciences Ltd - European Pharmaceutical Review

Takeda and Roivant launch Myovant Sciences Ltd European Pharmaceutical Review

$3B package deal to push Peninsula company into arms of Japanese drugmaker - The Business Journals

$3B package deal to push Peninsula company into arms of Japanese drugmaker The Business Journals

Myovant Sciences and Accord Healthcare enter into exclusive licence agreement to commercialise Orgovyx for prostate cancer in Europe - Express Pharma

Myovant Sciences and Accord Healthcare enter into exclusive licence agreement to commercialise Orgovyx for prostate cancer in Europe Express Pharma

Top Myovant Sciences Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant